Traitement médical de l’hyperplasie bénigne de la prostate : revue de littérature par le CTMH/AFU

Descazeaud, 2009, Traitement médical de l’hyperplasie bénigne de prostate, Prog Urol, 19, 890, 10.1016/j.purol.2009.09.006 Fitzpatrick, 2006, The natural history of benign prostatic hyperplasia, BJU Int, 97, 3, 10.1111/j.1464-410X.2006.06097.x Flanigan, 1998, 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study, J Urol, 160, 12, 10.1016/S0022-5347(01)63011-8 Brown, 2007, Self-management for men with lower urinary tract symptoms: randomised controlled trial, BMJ, 334, 25, 10.1136/bmj.39010.551319.AE Vallancien, 2008, Alfuzosin 10mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice, BJU Int, 101, 847, 10.1111/j.1464-410X.2008.07458.x Narayan, 1998, Overview of alpha-blocker therapy for benign prostatic hyperplasia, Urology, 51, 38, 10.1016/S0090-4295(98)00054-5 McNeill, 2005, Alfuzosin 10mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study, Urology, 65, 83, 10.1016/j.urology.2004.07.042 McConnell, 2003, The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia, N Engl J Med, 349, 2387, 10.1056/NEJMoa030656 Wilt, 2003, Tamsulosin for benign prostatic hyperplasia, Cochrane Database Syst Rev, 1, CD002081 Wilt, 2002, Terazosin for benign prostatic hyperplasia, Cochrane Database Syst Rev, 4, CD003851 Chapple, 2011, Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind placebo- and active-controlled clinical trial performed in Europe, Eur Urol, 59, 342, 10.1016/j.eururo.2010.10.046 Hellstrom, 2006, Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers, J Urol, 176, 1529, 10.1016/j.juro.2006.06.004 Clark, 2004, Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5-alpha reductase inhibitor, J Clin Endocrinol Metab, 89, 2179, 10.1210/jc.2003-030330 Zhu, 2009, 5-alpha reductase isozymes and androgen actions in the prostate, Ann N Y Acad Sci, 1155, 43, 10.1111/j.1749-6632.2009.04115.x Roehrborn, 2000, Urinary retention in patients with BPH treated with finasteride or placebo over 4years. Characterization of patients and ultimate outcomes. The PLESS Study Group, Eur Urol, 37, 528, 10.1159/000020189 Boyle, 1996, Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials, Urology, 48, 398, 10.1016/S0090-4295(96)00353-6 McConnell, 1998, The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride long-term efficacy and safety study group, N Engl J Med, 338, 557, 10.1056/NEJM199802263380901 Roehrborn, 2002, Efficacy and safety of a dual inhibitor of 5-alpha reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia, Urology, 60, 434, 10.1016/S0090-4295(02)01905-2 Thompson, 2003, The influence of finasteride on the development of prostate cancer, N Engl J Med, 349, 215, 10.1056/NEJMoa030660 Andriole, 2004, Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial, J Urol, 172, 1314, 10.1097/01.ju.0000139320.78673.2a Roehrborn, 2010, The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study, Eur Urol, 57, 123, 10.1016/j.eururo.2009.09.035 Debruyne, 2002, Comparison of a phytotherapeutic agent (Permixon) with an alpha-blocker (Tamsulosin) in the treatment of benign prostatic hyperplasia: a 1-year randomized international study, Eur Urol, 41, 497, 10.1016/S0302-2838(02)00066-0 Tacklind, 2009, Serenoa repens for benign prostatic hyperplasia, Cochrane Database Syst Rev, 2, CD001423 Wilt, 2002, Pygeum africanum for benign prostatic hyperplasia, Cochrane Database Syst Rev, 1, CD001044 Chapple, 2009, Tolterodine treatment improves storage symptoms suggestive of overactive bladder in men treated with alpha-blockers, Eur Urol, 56, 534, 10.1016/j.eururo.2008.11.026 Kaplan, 2006, Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial, JAMA, 296, 2319, 10.1001/jama.296.19.2319 MacDiarmid, 2008, Efficacy and safety of extended-release oxybutynin in combination with tamsulosin for treatment of lower urinary tract symptoms in men: randomized, double-blind, placebo-controlled study, Mayo Clin Proc, 83, 1002, 10.4065/83.9.1002 McVary, 2007, Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial, J Urol, 177, 1071, 10.1016/j.juro.2006.10.055 Stief, 2008, A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia, Eur Urol, 53, 1236, 10.1016/j.eururo.2008.01.075 Roehrborn, 2008, Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study, J Urol, 180, 1228, 10.1016/j.juro.2008.06.079 Liguori, 2009, Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report, J Sex Med, 6, 544, 10.1111/j.1743-6109.2008.01109.x